XML 20 R4.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Operations - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Revenues:                      
Revenue under collaborative research and development arrangements $ 476,586 $ 2,327,316 $ 1,889,988 $ 1,796,857 $ 1,820,643 $ 16,475,083 $ 4,335,236 $ 4,245,571 $ 6,490,747 $ 26,876,533 $ 7,416,568
Revenue under collaborative research and development arrangements with affiliated entity 189,278 574,596 499,720 137,000 375,000 125,000 166,667 112,500 1,400,594 779,167 479,464
Grants and miscellaneous revenue 7,735,428 9,410,648 3,814,083 6,176,298 3,739,919 7,583,151 784,775 808,566 27,136,457 12,916,411 2,560,734
Grants and miscellaneous revenue from affiliated entity 112,660 227,903 0 0         340,563 0 0
Total revenues 8,513,952 12,540,463 6,203,791 8,110,155 5,935,562 24,183,234 5,286,678 5,166,637 35,368,361 40,572,111 10,456,766
Operating expenses:                      
Research and development 23,911,731 26,980,343 19,630,801 18,189,160 15,601,891 16,075,201 16,688,511 9,426,320 88,712,035 57,791,923 34,095,039
General and administrative 6,965,517 5,755,603 5,799,530 5,371,613 4,860,086 4,377,616 4,718,260 4,107,928 23,892,263 18,063,890 15,857,688
Gain on sale of assets 0 0 (1,000,000) 0 0 0 (1,000,000) 0 (1,000,000) (1,000,000) 0
Total operating expenses 30,877,248 32,735,946 24,430,331 23,560,773 20,461,977 20,452,817 20,406,771 13,534,248 111,604,298 74,855,813 49,952,727
Loss from operations (22,363,296) (20,195,483) (18,226,540) (15,450,618) (14,526,415) 3,730,417 (15,120,093) (8,367,611) (76,235,937) (34,283,702) (39,495,961)
Other income (expense):                      
Interest and other income, net 191,460 391,596 341,131 333,070 (194,519) 214,982 146,332 138,276 1,257,257 305,071 331,461
Change in fair value of common stock warrants 644,888 2,690 (113,775) (406,249) (290,316) 518,877 (49,773) (1,227) 127,554 177,561 348,143
Gain on investment in affiliated entity (4,706,522) (958,141) (705,527) 7,480,977 (3,249,315) (659,054) 8,861,145 (2,352,309) 1,110,787 2,600,467 2,676,224
Net loss before income tax benefit $ (26,233,470) $ (20,759,338) $ (18,704,711) $ (8,042,820) (18,260,565) 3,805,222 (6,162,389) (10,582,871) (73,740,339) (31,200,603) (36,140,133)
Income tax benefit         308,520 1,789,246 0 0 0 2,097,766 0
Net loss         (17,952,045) 5,594,468 (6,162,389) (10,582,871) (73,740,339) (29,102,837) (36,140,133)
Net (income) loss attributable to non-controlling interest         0 0 (85,861) 1,092 0 (84,769) 18,420
Net loss attributable to Inovio Pharmaceuticals, Inc.         $ (17,952,045) $ 5,594,468 $ (6,248,250) $ (10,581,779) $ (73,740,339) $ (29,187,606) $ (36,121,713)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders                      
Basic ($ per share) $ (0.35) $ (0.28) $ (0.26) $ (0.11) $ (0.25) $ 0.08 $ (0.09) $ (0.17) $ (1.01) $ (0.43) $ (0.61)
Diluted ($ per share) $ (0.36) $ (0.28) $ (0.26) $ (0.11) $ (0.25) $ 0.07 $ (0.09) $ (0.18) $ (1.01) $ (0.44) $ (0.64)
Weighted average number of common shares outstanding used in per share calculations:                      
Basic (in shares)                 73,214,766 68,198,142 59,127,349
Diluted (in shares)                 73,214,766 68,365,265 59,408,252